BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iacob S, Cicinnati VR, Hilgard P, Iacob RA, Gheorghe LS, Popescu I, Frilling A, Malago M, Gerken G, Broelsch CE. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation. 2007;84:56-63. [PMID: 17627238 DOI: 10.1097/01.tp.0000267916.36343.ca] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Liu W, Yu B, Luo Y, Li J, Yuan X, Wu S, Liang B, Lv Z, Li Y, Peng X, Lu J, Peng X, Liu X. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model. BMC Cancer 2021;21:639. [PMID: 34051750 DOI: 10.1186/s12885-021-08381-8] [Reference Citation Analysis]
2 Shiba H, Hashimoto K, Kelly D, Fujiki M, Quintini C, Aucejo F, Uso TD, Yerian L, Yanaga K, Matsushima M, Eghtesad B, Fung J, Miller C. Risk stratification of allograft failure secondary to hepatitis C recurrence after liver transplantation. Hepatol Res 2016;46:1099-106. [PMID: 26833562 DOI: 10.1111/hepr.12661] [Reference Citation Analysis]
3 Melero JL, Berenguer M. Optimum minimization strategies in hepatitis C virus infected liver transplant: . Current Opinion in Organ Transplantation 2007;12:641-6. [DOI: 10.1097/mot.0b013e3282f1fbd9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Howell J, Angus P, Gow P. Hepatitis C recurrence: the Achilles heel of liver transplantation. Transpl Infect Dis. 2014;16:1-16. [PMID: 24372756 DOI: 10.1111/tid.12173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
5 Uemura T, Ramprasad V, Hollenbeak CS, Bezinover D, Kadry Z. Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant. 2012;12:984-991. [PMID: 22225523 DOI: 10.1111/j.1600-6143.2011.03899.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
6 Garcia-Saenz-de-Sicilia M, Olivera-Martinez MA, Grant WJ, Mercer DF, Baojjang C, Langnas A, McCashland T. Impact of anti-thymocyte globulin during immunosuppression induction in patients with hepatitis C after liver transplantation. Dig Dis Sci. 2014;59:2804-2812. [PMID: 24865255 DOI: 10.1007/s10620-014-3215-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619-633. [PMID: 21416659 DOI: 10.1111/j.1365-2036.2010.04570.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
8 Beckebaum S, Cicinnati VR. Conversion to combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy for renal dysfunction in liver transplant patients: never too late? Dig Dis Sci 2011;56:4-6. [PMID: 21049289 DOI: 10.1007/s10620-010-1449-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Ueda Y, Takada Y, Marusawa H, Haga H, Sato T, Tanaka Y, Egawa H, Uemoto S, Chiba T. Clinical features of biochemical cholestasis in patients with recurrent hepatitis C after living-donor liver transplantation. J Viral Hepat 2010;17:481-7. [PMID: 19804502 DOI: 10.1111/j.1365-2893.2009.01207.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Mas V, Maluf D, Archer KJ, Potter A, Suh J, Gehrau R, Descalzi V, Villamil F. Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation. Liver Transpl 2011;17:824-35. [PMID: 21618696 DOI: 10.1002/lt.22309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Coban S, Kekilli M, Köklü S. Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease. Inflamm Bowel Dis 2014;20:2142-50. [PMID: 25072501 DOI: 10.1097/MIB.0000000000000126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
12 McCashland TM. Management of liver transplant recipients with recurrent hepatitis C. Curr Opin Organ Transplant 2009;14:221-4. [PMID: 19444107 DOI: 10.1097/MOT.0b013e32832ade76] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Lai JC, Verna EC, Brown RS, O’Leary JG, Trotter JF, Forman LM, Duman JD, Foster RG, Stravitz RT, Terrault NA. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology. 2011;54:418-424. [PMID: 21538434 DOI: 10.1002/hep.24390] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
14 Yang H, Sherman M, Su J, Chen P, Liaw Y, Iloeje UH, Chen C. Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection. JCO 2010;28:2437-44. [DOI: 10.1200/jco.2009.27.4456] [Cited by in Crossref: 177] [Cited by in F6Publishing: 77] [Article Influence: 14.8] [Reference Citation Analysis]
15 Iacob S, Cicinnati VR, Lindemann M, Heinemann FM, Radtke A, Kaiser GM, Kabar I, Schmidt HH, Baba HA, Beckebaum S. Donor-Specific Anti-HLA Antibodies and Endothelial C4d Deposition-Association With Chronic Liver Allograft Failure. Transplantation 2015;99:1869-75. [PMID: 25706274 DOI: 10.1097/TP.0000000000000613] [Cited by in Crossref: 30] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
16 Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, Piscaglia F, Tamè M, Pinna AD. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl. 2009;15:782-789. [PMID: 19562715 DOI: 10.1002/lt.21760] [Cited by in Crossref: 68] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
17 Valadao RM, Terrault NA. Older donors: Mounting risks for the hepatitis C-infected liver transplant recipient?: Editorial. Liver Transpl 2009;15:677-81. [DOI: 10.1002/lt.21801] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
18 Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014;88:1351-1389. [PMID: 24792322 DOI: 10.1111/j.1432-2277.2011.01250.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
19 Jiménez-Romero C, Caso Maestro O, Cambra Molero F, Justo Alonso I, Alegre Torrado C, Manrique Municio A, Calvo Pulido J, Loinaz Segurola C, Moreno González E. Using old liver grafts for liver transplantation: Where are the limits? World J Gastroenterol 2014; 20(31): 10691-10702 [PMID: 25152573 DOI: 10.3748/wjg.v20.i31.10691] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
20 Smallwood GA, Devine R, Fasola C, Stieber AC, Heffron TG. Does interferon use prior to liver transplant influence hepatitis C outcomes following transplantation? Transplantation 2008;86:1795-8. [PMID: 19104424 DOI: 10.1097/TP.0b013e3181914188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
21 de Arias AE, Haworth SE, Belli LS, Burra P, Pinzello G, Vangeli M, Minola E, Guido M, Boccagni P, De Feo TM. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl. 2009;15:390-399. [PMID: 19326408 DOI: 10.1002/lt.21673] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
22 Jiménez-romero C, Clemares-lama M, Manrique-municio A, García-sesma A, Calvo-pulido J, Moreno-gonzález E. Long-Term Results Using Old Liver Grafts for Transplantation: Sexagenerian Versus Liver Donors Older than 70 Years. World J Surg 2013;37:2211-21. [DOI: 10.1007/s00268-013-2085-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
23 Beckebaum S, Sotiropoulos GC, Klein CG, Broelsch CE, Saner F, Paul A, Gerken G, Cicinnati VR. Predictive Factors of Outcome in Patients Transplanted for Hepatitis B. Transplantation 2009;87:872-81. [DOI: 10.1097/tp.0b013e31819a6697] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT. Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transpl Int. 2015;28:980-989. [PMID: 25818896 DOI: 10.1111/tri.12568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
25 Allard M, Lopes F, Frosio F, Golse N, Sa Cunha A, Cherqui D, Castaing D, Adam R, Vibert E. Extreme large-for-size syndrome after adult liver transplantation: A model for predicting a potentially lethal complication. Liver Transpl 2017;23:1294-304. [DOI: 10.1002/lt.24835] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
26 van der Laan LJ, Hudson M, McPherson S, Zondervan PE, Thomas RC, Kwekkeboom J, Lindsay AS, Burt AD, Kazemier G, Tilanus HW, Bassendine MF, Metselaar HJ. Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. Transplant Proc 2010;42:4573-7. [PMID: 21168740 DOI: 10.1016/j.transproceed.2010.10.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
27 Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014;88:1351-1389. [PMID: 24792322 DOI: 10.1007/s00204-014-1247-1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 12.6] [Reference Citation Analysis]